Company Analysis
Sign in

Kazia Therapeutics Limited (KZIA)

Nasdaq: KZIA · Pharmaceutical Preparations · filing with the SEC since 2002
Full chart Alerts Compare
Grade3.0
◀ Past 2.8● Present 2.5▶ Future 3.6
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In Australian dollars (AUD), as filed; per-share figures in Australian dollars; share counts. The fiscal year ends in June.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period endingJun 30, 2025Jun 30, 2024Jun 30, 2023Jun 30, 2022Jun 30, 2021Jun 30, 2020Jun 30, 2019Jun 30, 2018Jun 30, 2017Jun 30, 2016
Report filedNov 7, 2025Nov 15, 2024Oct 26, 2023Oct 17, 2022Oct 7, 2021Oct 22, 2020Oct 21, 2019Oct 24, 2018Oct 25, 2017·
Revenue42,0002,308,0000015,183,000··119,000249,000406,000
Research and development7,326,00017,380,00015,564,00020,169,000r14,541,0009,494,0006,475,000r9,774,00011,136,0009,894,000
Selling, general and administrative8,720,00013,563,0008,583,0005,113,000r7,020,000r3,690,0003,785,000r5,598,0008,529,0005,761,000
Finance costs·······01,000r0
Finance income72,00012,00022,0002,00042,00066,000100,000119,000249,000406,000
Income before income taxes-22,448,000-27,049,000-20,736,000-25,382,000r-8,904,000r-12,765,000-10,568,000-6,344,000-10,869,000-12,155,000
Income tax expense-1,746,000-271,000-271,000-368,000-484,000-298,000-298,000-305,000-199,000·
Net income-20,702,000-26,778,000-20,465,000r-25,014,000r-8,420,000r-12,467,000-10,270,000-6,039,000-10,670,000-12,155,000
Net income to non-controlling interests·········-92,000
Net income to shareholders-20,702,000-26,778,000-20,465,000-25,014,000r-8,420,000r-12,467,000-10,270,000-6,039,000-10,670,000-12,063,000
Earnings per share, basic-0.0378-0.1016-0.1123-0.1888r-0.0716r-0.1707r-17.86-12.48-2.28-2.82
Earnings per share, diluted-0.0378-0.1016-0.1123-0.1888r-0.0716r-0.1707r-17.86-12.48-2.28-2.82
Weighted average shares, basic··184,284,350132,467,686117,674,54373,053,51457,503,55548,376,525467,833,849427,431,910
Weighted average shares, diluted547,941,171263,676,313184,284,350132,467,686117,674,54373,053,51457,503,55548,376,525467,833,849427,431,910
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldifrs-full:Revenue
ifrs-full:RevenueFromContractsWithCustomers
Research and development spent on inventing what it sells nextifrs-full:ResearchAndDevelopmentExpense
Selling, general and administrative the cost of selling and of running the companyifrs-full:SellingGeneralAndAdministrativeExpense
Finance costs what its borrowing costifrs-full:InterestExpense
Finance income what its cash and investments earnedifrs-full:FinanceIncome
ifrs-full:RevenueFromInterest
Income before income taxes profit before taxifrs-full:ProfitLossBeforeTax
Income tax expense tax charged on the period's profitifrs-full:IncomeTaxExpenseContinuingOperations
Net income the whole group's profit, minority holders' share includedifrs-full:ProfitLoss
Net income to non-controlling interests the share that belongs to minority holdersifrs-full:ProfitLossAttributableToNoncontrollingInterests
Net income to shareholders the profit or loss that belongs to the company's shareholdersifrs-full:ProfitLossAttributableToOwnersOfParent
Earnings per share, basic net income per share outstandingifrs-full:BasicEarningsLossPerShare
Earnings per share, diluted net income per share, counting every share that could be issuedifrs-full:DilutedEarningsLossPerShare
Weighted average shares, basic the average count of shares outstandingifrs-full:WeightedAverageShares
Weighted average shares, diluted the average count with every share that could be issuedifrs-full:AdjustedWeightedAverageShares
SI Assistanton KZIA · research, not advice